Tantum Verde mouth rinse

PreclinicalSmall molecule

Tantum Verde mouth rinse is one of 4 small molecule programs targeting Recurrent aphthous stomatitis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Recurrent Aphthous StomatitisActive, not recruiting

Recurrent Aphthous StomatitisPreclinical

Active, not recruiting

Competition

Competitive Landscape

3 competitors in Recurrent Aphthous Stomatitis

#DrugCompanyPhaseTrials

Otezla

Amgen

Approved

1 2

Kenalog

BBausch Health Americas, Inc.

Approved

—3

Trental

VValidus Pharmaceuticals

Preclinical

1 4

Tantum Verde mouth rinse

AAin Shams University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Recurrent aphthous stomatitis1 trial

A Study on Sumac Mouth Rinse for Treating Recurrent Aphthous Stomatitis

Completed·—·N/A·NCT07229469·38 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Tantum Verde mouth rinse. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tantum Verde mouth rinse compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tantum Verde mouth rinse. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ain Shams University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: AAin Shams University

Tantum Verde mouth rinse

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Recurrent aphthous stomatitis1 trial

References

Drug Info

Quick Facts

Related News